In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Two of the vaccines we have for COVID-19 have the distinction of being the first mRNA vaccines to see widespread use in ...

The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...

Dr. Robert Malone — a member of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices ...

COVID-19 proved that mRNA vaccines can work. Now, researchers are applying the technology to other diseases. More than half of Americans are fully vaccinated against COVID-19. Many of them received an ...